U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases announces the availability of funding for implementation of the Development of Novel Therapeutics for Select Pathogens (R21/R33) Grant. The purpose of this grant is to support basic to translational research focused on development of novel therapeutics against select antibiotic resistant gram-negative bacteria or influenza. Contractors should refer to Section VII, Agency Contacts, in the RFP for information regarding each Institute's grants management contact for this program . . .

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

RFP | June 25, 2014

Federal Government Announces Development of Novel Therapeutics for Select Pathogens (R21/R33) Grant Funding

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member